## **Gigliola Reato**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8838777/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer. Journal of the National Cancer Institute, 2011, 103, 645-661.	6.3	300
2	The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature, 2005, 434, 396-400.	27.8	245
3	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood, 2002, 99, 856-862.	1.4	155
4	The <i>MET</i> Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype. Cancer Research, 2012, 72, 4537-4550.	0.9	120
5	MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors. Cancer Research, 2014, 74, 1857-1869.	0.9	120
6	<scp>MET</scp> inhibition overcomes radiation resistance of glioblastoma stemâ€like cells. EMBO Molecular Medicine, 2016, 8, 550-568.	6.9	74
7	IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 1999, 104, 589-599.	2.5	58
8	Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils. International Journal of Antimicrobial Agents, 2004, 23, 150-154.	2.5	54
9	TNFâ€Î± promotes invasive growth through the MET signaling pathway. Molecular Oncology, 2015, 9, 377-388.	4.6	40
10	Human herpesvirus type 7 in Hodgkin's disease. British Journal of Haematology, 1998, 101, 492-499.	2.5	27
11	Somatic alterations of the androgen receptor CAG repeat in human colon cancer delineate a novel mutation pathway independent of microsatellite instability. Cancer Genetics and Cytogenetics, 2000, 123, 35-40.	1.0	24
12	A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. Clinical Cancer Research, 2018, 24, 807-820.	7.0	23
13	ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell Reports, 2021, 36, 109455.	6.4	18
14	Antibodies Binding Granulocyte–Macrophage Colony Stimulating Factor Produced by Cord Blood-Derived B Cell Lines Immortalized by Epstein–Barr Virus in Vitro. Cellular Immunology, 2000, 204, 114-127.	3.0	11
15	Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures. Cancer Gene Therapy, 2000, 7, 167-176.	4.6	6
16	Naturally-occurring anti-G-CSF antibodies produced by human cord blood B-cell lines infected with Epstein-Barr virus. The Hematology Journal, 2001, 2, 161-171.	1.4	2
17	Immunoglobulin Light Chain Restriction and Clonal Rearrangement in Nodular Paragranuloma. Leukemia and Lymphoma, 1994, 14, 515-520.	1.3	1
18	<i>In situ</i> hybridization evidence of the donor origin of a postâ€ŧransplant lymphoproliferative disorder. European Journal of Haematology, 1999, 63, 61-63.	2.2	1